Utama › Karsinoma Urotelial (Sel Transisi) › Tennessee › Nashville
Kajian klinikal Karsinoma Urotelial (Sel Transisi) di Nashville, TN
23 kajian untuk Karsinoma Urotelial (Sel Transisi) sedang mencari peserta di lokasi dalam dan sekitar Nashville (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1
- Tennessee Oncology, Nashville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Mengambil pesertaFasa 1
- Exelixis Clinical Site #3, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Mengambil pesertaFasa 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Mengambil pesertaFasa 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Mengambil pesertaFasa 3
- SCRI Oncology Partners, Nashville
DBC-664 in Adult Patients With Solid Tumors
Mengambil pesertaFasa 1
- SCRI Oncology Partners, Nashville
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Mengambil pesertaKajian pemerhatian
- Vanderbilt University Medical Center, Nashville
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Mengambil pesertaFasa 1/2
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology, Nashville
- dan 9 lagi
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Mengambil pesertaFasa 1
- Sarah Cannon Research Institute, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Mengambil pesertaFasa 1/2
- Vanderbilt University Medical Center, Nashville
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Mengambil pesertaFasa 3
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Mengambil pesertaFasa 2/3
- Research Site, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Mengambil pesertaFasa 1
- Sarah Cannon Research Institute, Nashville
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Mengambil pesertaFasa 1/2
- Tennessee Oncology, Nashville
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Mengambil pesertaFasa 2/3
- Research Site, Nashville
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Mengambil pesertaFasa 1
- Vanderbilt- Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Mengambil pesertaFasa 1/2
- SCRI Oncology Partners, Nashville
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Mengambil pesertaFasa 3
- Research Site, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Mengambil pesertaFasa 2
- SCRI Oncology Partners, Nashville
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Mengambil peserta
- Vanderbilt University Medical Center, Nashville
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Mengambil pesertaFasa 2
- Site 02-007 - Urology Associates, P. C, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Nashville
Kajian Karsinoma Urotelial (Sel Transisi) di bandar lain
- New York City, NY22 kajian
- Houston, TX19 kajian
- Dallas, TX18 kajian
- Edison, NJ18 kajian
- Los Angeles, CA17 kajian
- Queens, NY15 kajian
- Chicago, IL14 kajian
- Arlington, VA12 kajian
- Boston, MA11 kajian
- San Antonio, TX11 kajian
- Austin, TX10 kajian
- Orange, CA10 kajian
Kajian lain di Nashville
- Kanser Paru-paru Bukan Sel Kecil97 kajian
- Kanser Payudara81 kajian
- Kanser Metastatik70 kajian
- Kanser Kolorektal69 kajian
- Kanser (semua jenis)65 kajian
- Kanser Ovari49 kajian
- Kanser Prostat43 kajian
- Kanser Paru-paru40 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher39 kajian
- Kanser Pankreas39 kajian
- Kanser Endometrium38 kajian
- Melanoma33 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.